Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure BioSciences reaches a deal to contract out its PreEMT platform

The hope is that the PreEMT platform can be used to manufacture and improve the quality of a key protein-based drug
A scientist and a patient
PreEMT platform helps drug companies to develop protein-based therapeutics

Pressure BioSciences Inc (OTCMKTS:PBIO), a life-science group that makes instruments which utilize pressure to control bio-molecular interactions, has signed a deal with an unnamed international biopharmaceutical company, which will assess the potential of its PreEMT platform.

The hope is that the PreEMT platform – which uses high pressure to help drug companies develop protein-based therapeutics - can be used to manufacture and improve the quality of a key protein-based drug, which is currently under development at the undisclosed biopharmaceutical group.

The manufacture of therapeutic proteins is difficult and complex and producing a typical protein drug may include more than 5,000 steps. As a result, even in the best laboratories, it is typical for protein therapeutics to fail in manufacturing.   

“We believe this unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality novel protein therapeutics and lower the cost of existing formulations," said Dr. Alexander Lazarev, vice president of research & development. “PreEMT can be applied to many therapeutic proteins. … It is scaleable and practical for standard manufacturing processes.”

READ: Pressure BioSciences CEO says company poised for 'solid year' in 2018

Richard Schumacher, Pressure BioScience’s president and chief executive, said the contract with the international biopharma group will be wrapped up in three to four months.  He noted that several other biopharmaceutical companies are interested in evaluating the group’s PreEMT platform and said that if deals are done, Pressure BioScience will receive royalty revenues.

“Should the PreEMT technology result in more efficient production of high quality protein-based therapeutics for any biopharmaceutical company developing new protein-based therapeutics, manufacturing-scale licenses have the potential to generate millions of dollars in annual royalty revenue,” Schumacher said.

There are over 200 therapeutic proteins and peptides now approved for clinical use in the U.S. These drugs have changed therapy options for cancer and blood disorders and are also a treatment option for autoimmune diseases.

Pressure BioScience’s shares were flat at US$3.75 in early afternoon trade.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use